Immunotherapy with interleukin 2 after ABMT in AML.

Abstract

Myeloablative chemo (+/- radio) therapy and rescue with ABMT has been used as final consolidation therapy in 18 patients with AML in first remission. In seven (6 autologous, 1 syngeneic) marrow reinfusion was followed by iv IL-2. One patient, who commenced IL-2 4 days after BMT, died from pulmonary oedema due to the capillary leak syndrome. Thereafter, treatment with IL-2 was delayed until the platelet count reached 30 x 10(9)/l. All patients developed reversible hypotension (treated with infusion of colloid), but treatment was otherwise well tolerated. With 21-58 months (median 32 months) from the time of ABMT there has been one relapse (actuarial risk 17%, 95% confidence intervals (CI) 3-31%). The disease-free survival is 71% (95% CI 38-100%). Eleven patients with comparable remission induction and consolidation therapy, and an identical interval between diagnosis and ABMT (5-11 months, median 6 months) received an autograft without immunotherapy. With 24-45 months (median 29 months) follow-up the actuarial disease-free survival is 36% (95% CI 8-64%), the actuarial relapse risk is 54% (95% CI 18-90%). We conclude that immunotherapy given after ABMT to patients with AML in first remission when the platelet count exceeds 30 x 10(9)/l is safe and may induce an immunological environment which results in the elimination of residual leukaemia.

• Authors: M D Hamon, H G Prentice, D J Gottlieb, I D Macdonald, J M Cunningham, O P Smith, M Gilmore, L Gandhi, C Collis
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 11 Issue 5 Pg. 399-401 (May 1993) ISSN: 0268-3369 [Print] England
• PMID: 8504274 (Publication Type: Journal Article)

Chemical References

• Interleukin-2

Topics

• Adolescent
• Adult
• Bone Marrow Transplantation
• Combined Modality Therapy
• Humans
• Immunotherapy
• Interleukin-2 (therapeutic use)
• Leukemia, Myeloid, Acute (surgery, therapy)
• Middle Aged
• Remission Induction